Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @CcsNybc
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @CcsNybc
-
First human trial of monoclonal antibody to prevent
#malaria opens. The phase I trial will give subjects mAb CIS43LS which may confer temporary immunity against the disease. This would be useful for travelers in endemic areas. Read more here ==> http://bit.ly/MalariamAb#researchHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
PACT Pharma strives to expand their manufacturing operations of
#CellTherapy products, raising $75 million in their Series C financing round. Read about how they plan to develop new cell therapies that target solid tumors ==>http://bit.ly/PACTCellTher#biotech#healthcarepic.twitter.com/XFSU9h0YnT
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Results presented at the American Society of
#Hematology from a clinical trial show the experimental#immunotherapy CS1001 proving effective at combating extranodal natural killer T-cell lymphoma (#ENKTL) Learn about the immune checkpoint inhibitor here ==>http://bit.ly/ENKTLHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Lab findings have prompted a clinical trial in which scientists strive to find out if
#immunotherapies can be used to bolster the effect of#CheckpointBlockadeTherapy in#lymphoma. Listen to Dr. Joshua Brody talk about the possibilities of#TCellTherapy ==>http://bit.ly/nHLTherHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Analysis of over 48,000 patients at MA General Hospital shows that age & sex may play a role in the optimal and deficient levels of iron in the blood. Find out what groups had a lower threshold for iron deficiency here ==> http://bit.ly/FerDef
#hematology#healthcareHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Sorrento and#Celularity have announced a collaboration to develop an#allogeneic natural killer T-cell therapy for the prevention and treatment of the 2019 Novel#Coronavirus. Learn more about their plans for the CYNK-001 therapy ==>http://bit.ly/CoVTher#CoV#biotechHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
UVA Scientists state they have successfully used
#GeneTherapy to treat age-related macular degeneration in mice.#AMD is the leading cause of vision loss in people older than 60. Find out how the scientists used the DICER1 enzyme to treat it ==> http://bit.ly/AMDGeneTher pic.twitter.com/snjQDY5Boe
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
New
#GeneTherapy In Mice Could Offer Lasting Protection Against Nerve Agents. Researchers arm mice with "bioscavengers" that seek and destroy nerve agents, granting immunity. Read how a liver enzyme could neutralize nerve agents like sarin ==> http://bit.ly/NerveGeneTher#biotechpic.twitter.com/cPx5jJamLv
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#Pharmaceutical#Takeda is currently developing a#Hemophilia A#GeneTherapy, TAK-754, currently in phase I of clinical trials. Takeda’s head of R&D states he believes it likely won’t be a frontrunner in the market ==> http://bit.ly/TakGeneTher#biotech#healthcareHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
According to St Jude Children’s Research Hospital and the Chinese Children’s Cancer Group, a phase III trial shows that
#chemotherapy plus#desatinib is more effective at controlling#ALL than#imatinib. Read the full study here ==>http://bit.ly/Desatinib#Oncology#HealthcareHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Biomaterial-based vaccine eliminates acute myeloid
#leukemia in mice. A solid vaccine made of#cryogel and AML-specific antigens produced T-cell numbers 6X higher than traditional therapies. Read the Harvard researchers’ unexpected results ==>http://bit.ly/AMLVax#biotech#AMLpic.twitter.com/LV3yp3Cjmw
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A case report of a man in France claims his rare IgE-producing
#MultipleMyeloma developed into IgE-producing#PlasmaCellLeukemia. The first sign of something awry was the detection of a kappa light chain monoclonal gammopathy. Read more here ==> http://bit.ly/MyeLeuk#OncologyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
In an early clinical trial, three
#SickleCell patients who received autologous#CD34+ cells engineered to promote#FetalHemoglobin production fared better than those who receive traditional therapies. Read the results presented at ASH’s annual meeting ==>http://bit.ly/BCL11AHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#BioMarin Sets Gene Therapy Sights Beyond Hemophilia. In the wake of#Valrox’s price tag announcement, the#biotech Co. plans to begin human testing of#genetherapies for rare disorder#phenylketonuria. Read about their plans here ==>http://bit.ly/BiomarinPKU#Pharma#Healthcarepic.twitter.com/pCJgJKoxg5
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
FDA Names Potential
#GeneTherapy for Sickle Cell an ‘Orphan Drug.’ ARU-1801 stimulates the production of fetal hemoglobin instead of adult hemoglobin. Read what#OrphanDrug status means for the therapy here ==>http://bit.ly/SCDOrphanDrug#biotech#healthcare#SickleCellHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
New
#GeneTherapy for Hemophilia A could be the most expensive drug ever. If FDA approved, Valrox from#BioMarin could cost $2-3 million per dose. This would be the 3rd gene therapy ever approved in the US. http://bit.ly/HemoGeneTher <--Hear what BioMarin’s chief has to say.#biotechHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A trending topic in the
#CellandGeneTherapy world and a must read: "How the Increased Need for Allogeneic Donors Could Impact Cell Therapy Research" http://bit.ly/AllogeneicDonorIncrease … Blog written by our medical director Patricia Shi, MD.#biotechnology#biotech#CellularTherapyExpertspic.twitter.com/Mj00jwY7iW
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
FT-4202, experimental
#SickleCellDisease therapy, performs well in phase I of clinical trials. The drug activates PKR, which increases hemoglobin’s affinity to oxygen. Read the trial’s findings here ==>http://bit.ly/SCDFT-4202#clinicaltrials#biotech#SCD#research#biotechpic.twitter.com/cv6CY28IRt
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#LabCorp unveils new#GeneTherapy offerings from#Covance. “It becomes even more critical to find innovative ways to help our customers speed these transformational therapies to the patients who need them,” -Paul Kirchgraber. Learn more ==> http://bit.ly/LabCorpCellTher pic.twitter.com/NCAqKyWnMh
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Charles Hough suffered from
#SickleCellDisease most of his life. In 2018, scientists injected his own edited#StemCells into his body & reduced his proportion of sickled cells from 97% to 37%. Hear Charles’s story of life after#GeneTherapy ==>http://bit.ly/SCDGeneTher#Biotechpic.twitter.com/PGt0bVWkIp
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.